Pharmaceuticals News and Research

RSS

Impax submits IPX066 NDA to FDA for treatment of Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.

22 Dec 2011

Agilent acquires BioSystem Development business

Agilent Technologies Inc. today announced it has completed the acquisition of the BioSystem Development business. BioSystem Development is a privately held company that develops and manufactures the AssayMAP Microchromatography platform to meet the analytical needs of the life sciences industry.

22 Dec 2011

New pharma title from iSmithers ‘Update on Polymers for Ocular Drug Delivery’

The eye is the most easily accessible site for topical administration of a medication. Drugs are commonly applied to the eye for localised action on the surface or in the interior of the eye. A major problem in ocular therapeutics is the attainment of an optimal drug concentration at the site of action.

21 Dec 2011

Actavis enters LOI with QRxPharma to commercialize MoxDuo IR in the U.S.

Actavis Group, the international generic pharmaceuticals company, today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited to commercialize MoxDuo IR in the United States.

21 Dec 2011

Scientists identify why African naked mole-rat feels no pain when exposed to acid

British researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have found out why the African naked mole-rat (Heterocephalus glaber), one of the world's most unusual mammals, feels no pain when exposed to acid.

21 Dec 2011

University of Western Ontario receives FDA approval to begin SAV001 HIV trial

The first and only preventative HIV vaccine based on a genetically modified killed whole virus has received approval by the United States Food and Drug Administration (FDA) to start human clinical trials.

21 Dec 2011

Ranbaxy signs consent decree with U.S. FDA

Ranbaxy Laboratories Ltd. today announced that it has signed a consent decree with the U.S. Food and Drug Administration.

21 Dec 2011

GSK, ProteoTech enter R&D agreement to develop new Parkinson's therapeutics

ProteoTech, Inc., a privately held biotechnology company, has entered into a drug development agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on ProteoTech's small molecule technology platform against misfolded proteins to specifically advance work on its alpha-synuclein therapeutic program for the treatment of Parkinson's disease and other synucleinopathies.

21 Dec 2011

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.

21 Dec 2011

Takeda enters agreement to acquire Intellikine

Takeda Pharmaceutical Company Limited and Intellikine, Inc. today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda, and Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash.

21 Dec 2011

Amgen and Watson to collaborate on biosimilar anti-cancer drugs

Amgen, the largest standalone biotechnology company, and generic drug firm Watson Pharmaceuticals will collaborate on developing biosimilar drugs for cancer.

20 Dec 2011

EETs may also drive growth and spread of cancer

A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.

20 Dec 2011

Pfizer, GlaxoSmithKline to increase sales of pneumococcal vaccines through GAVI

Pharmaceutical companies Pfizer and GlaxoSmithKline are increasing their sales of reduced-cost pneumonia vaccines to developing countries through the GAVI Alliance "by more than 50 percent, marking the scale-up of an international program to protect millions of children," Reuters reports.

20 Dec 2011

Even as it faces attack, health law implementation — and challenges — continue

The Hill and Reuters report on the health law's numerous 2012 battle fronts - starting with the Supreme Court's review of the law and moving toward the November elections. Meanwhile, however, other news outlets report on continuing implementation of the measure, including the creation of a federal health exchange and defense of its prevention fund.

20 Dec 2011

Impax commences IPX159 Phase IIb trial in Restless Legs Syndrome

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., announced that it has initiated a Phase IIb trial of its drug candidate IPX159 in patients with moderate to severe Restless Legs Syndrome.

20 Dec 2011

First nutrition and cognition research center

Abbott and the University of Illinois at Urbana-Champaign announced today they have established the first-ever multi-disciplinary nutrition and cognition research center, which will be located on the Urbana campus. The Center for Nutrition, Learning, and Memory will lead directed and-solicited research on the impact of nutrition on learning and memory in the human brain.

19 Dec 2011

Weight loss pill without major side effects coming soon

Scientists are on their way to develop a perfect diet pill. The drug, which switches off appetite using hormones that are created naturally in the stomach when it is full, could be the first to be effective in weight loss without side effects.

19 Dec 2011

Gardasil – cervical cancer vaccine offered to all boys as well

Soon all adolescent boys may be vaccinated against the sexually transmitted disease that causes some forms of cancer under an extension of a scheme now available to girls, the Australian government's expert panel has recommended. The committee adds that the shots would also widen immunity to the virus, which would further reduce the risk to women and stem the spread of genital warts in both sexes.

19 Dec 2011

Phase I clinical study of Selexys SelG1 for sickle cell disease completed

Selexys Pharmaceuticals announced today that it has completed a Phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

19 Dec 2011

EMA CHMP recommends approval for BioMarin's Novato manufacturing facility expansion

BioMarin Pharmaceutical Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval for the company's manufacturing facility expansion in Novato, CA.

19 Dec 2011